Formulation development of a combined tablet of Rosa damascena, and investigating its effectiveness on the clinical symptoms of functional dyspepsia patients: a randomized. Double-blind controlled trial

开始日期2025-01-11

申办/合作机构

Babol University of Medical Sciences

IRCT20240602061980N2

/ Recruiting临床3期IIT

Comparison of pain perception during surfactant administration in two different methods (MIST, INSURE) in preterm infants with respiratory distress syndrome: a randomized clinical trial

开始日期2024-12-21

申办/合作机构

Babol University of Medical Sciences

100 项与 Babol University of Medical Sciences 相关的临床结果

登录后查看更多信息

0 项与 Babol University of Medical Sciences 相关的专利（医药）

登录后查看更多信息

6,410

项与 Babol University of Medical Sciences 相关的文献（医药）

2025-12-01·Journal of Clinical Immunology

Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis

Review

作者: Abolhassani, Hassan ; Mohtashami, Maryam ; Esfahani, Zahra Hamidi ; Saeedi-Boroujeni, Ali ; Fekrvand, Saba ; Rezaei, Nima ; Amiri, Mahboube ; Salehi, Helia ; Fathi, Nazanin ; Almasi-Hashiani, Amir ; Ahangarzadeh, Milad ; Azizi, Gholamreza ; Khanmohammadi, Shaghayegh ; Saleki, Kiarash ; Yazdani, Reza ; Razavi, Azadehsadat ; Fard, Najmeh Nameh Goshay ; Heidari, Arash ; Hassanpour, Gholamreza

BACKGROUNDPatients with inborn errors of immunity (IEI) are susceptible to developing cancer due to defects in the immune system. The prevalence of cancer is higher in IEI patients compared to the immunocompetent population and cancers are considered as an important and common cause of death in IEI patients.OBJECTIVESTo systematically review demographic, genetic and cancer-related data of IEI patients with a history of malignancy. Moreover, we performed a meta-analysis aiming to determine the frequency of cancer in patients with different types of IEI.METHODSWe conducted electronic searches on Embase, Web of Science, PubMed, and Scopus (until September 2023) introducing terms related to IEI and cancer. Studies with human subjects with confirmed IEI who had developed at least one malignancy during their lifetime were included.RESULTSA total number of 4607 IEI patients with a cancer history were included in the present study. Common variable immunodeficiency (CVID) had the highest number of reported cases (1284 cases), mainly due to a higher relative proportion of patients with predominantly antibody deficiencies (PAD) and their increased life expectancy contributing to the higher detection and reporting of cancers among these patients. The most common malignancy was hematologic/blood cancers (3026 cases, mainly diffuse large B cell lymphoma). A total number of 1173 cases (55.6%) succumbed to cancer, with the highest rate of bone marrow failure (64.9%). Among the patients with monogenic defects in IEI-associated genes, the majority of cases had ATM deficiency (926 cases), but the highest cancer frequency rate belonged to NBS1 deficiency (50.5%). 1928 cases out of total 4607 eligible cases had detailed data to allow further statistical analysis that revealed BRCA2 deficiency had the earliest cancer development (~ 38 months), lowest cure frequency, and highest fatality rate (85%), while ATM deficiency had the lowest cure frequency and highest fatality rate (72%) among total cases reviewed with exclusion of Fanconi anemia.CONCLUSIONThe overall reported cancer frequency in the cases reviewed with and without exclusion of Fanconi anemia was 11.1% (95% confidence interval: 9.8-12.5%) and 12.0% (95% confidence interval: 10.6-13.5%), respectively. Our study revealed that the incidence of cancer is significantly dependent on the molecular and pathway defects in IEI patients, and individualized early screening and appropriate treatment, might improve the prognosis of these patients.

2025-09-01·Journal of Behavior Therapy and Experimental Psychiatry

Efficacy of internet-based emotion-focused cognitive behavior therapy (IECBT) in improving stress and anxiety of women with suspected fetal malformation: A randomized controlled trial

Article

作者: Rayati, Mostafa ; Barat, Shahnaz ; Adib-Rad, Hajar ; Taheriotaghsara, Seyedsina ; Khafri, Soraya ; Nasiri-Amiri, Fatemeh ; Pahlavan, Zeinab ; Faramarzi, Mahbobeh ; Aligoltabar, Sajede

BACKGROUND AND OBJECTIVESAnxiety is prevalent among pregnant women with suspected fetal malformation. Hence, this study aimed to assess the effectiveness of IECBT in alleviating pregnancy-specific stress and anxiety in anxious women with suspected fetal malformation.METHODSA randomized four-arm parallel-group controlled trial was conducted involving 140 pregnant women displaying anxiety symptoms before 20 weeks of gestation and suspected fetal malformation. Participants were randomly allocated into four groups, each consisting of 35 women: IECBT alone, IECBT with booster sessions, IECBT with spouse participation, and IECBT combined with spouse participation and booster sessions. The IECBT intervention comprised six 50-min therapist-led sessions for women, with an additional 20-min session for men in the IECBT with spouse participation group. Those in the IECBT with booster sessions groups received six monthly 50-min sessions post-intervention until delivery. Five questionnaires-Spielberger's State Anxiety, Pregnancy-Specific Stress, Uncertainty Intolerance, and Emotion Regulation-were administered before the trial, upon completion of the 6-week intervention, and at 3-month and 6-month post-trial follow-ups.RESULTSThe IECBT interventions led to significant improvements in anxiety symptoms, pregnancy-specific stress, uncertainty intolerance, and emotional regulation after therapy, with these improvements sustained at the 3-month and 6-month post-treatment assessments. However, no superiority was observed among the four IECBT models across the three measurement intervals-post-trial, 3-month, and 6-month follow-ups regarding outcome improvement. Additionally, participants expressed high satisfaction levels with all IECBT approaches, with no significant differences noted among the four groups.LIMITATIONIECBT with spouse participation and IECBT with booster sessions were not therapist-guided, results might stem from the masculism culture of the population and their low responsibility and assistance in solving pregnant women's problems, especially during pregnancy, the lack of long-term follow-up of treatment effectiveness and postnatal psychological outcomes with or without fetal malformation.CONCLUSIONSThe findings suggest that the four models of IECBT improved anxiety, stress, uncertainty, and dysregulated emotions in women with suspected fetal malformation, and such improvements remained stable up to six months after the intervention.

2025-08-01·Anti-Cancer Agents in Medicinal Chemistry

A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy

Article

作者: Jadidi-Niaragh, Farhad ; Dashti, Mohsen ; Ahmadpour, Mahsa ; Mahalleh, Mehrdad ; Alinejad, Erfan ; Lorestani, Parsa ; Habibi, Mohammad Amin ; Robat-Jazi, Behrouz ; Nejati, Negar ; Hamidieh, Amir Ali ; Mohammadi, Shiva

Background:Despite ongoing advances and introducing innovative therapeutic approaches for the treatment of multiple myeloma (MM), relapses are common, with low overall survival rates. G protein–coupled receptor, class C, group 5, and member D (GPRC5D) has been expressed in several myeloma cell lines and has demonstrated encouraging outcomes results in in-vitro studies as a potential target for immunotherapies.Objective:We aimed to investigate the safety and efficacy of GPRC5D-targeted CAR T cell therapies in MM patients.Methods:On August 24, 2023, the databases of PubMed, Scopus, Embase, and Web of Science were systematically searched for pertinent studies. After completing a two‐step title/abstract and full-text screening process, the eligible studies were included.Results:Following the screening of 107 articles, four studies of 130 multiple myeloma patients treated with GPRC5D-targeted CAR T-cell therapy were included. The meta-analyses showed an ORR of 87% (95% CI [81- 93%]), with 74% (95% CI [65-73%]) for those with prior BCMA-targeted therapy and 88% (95% CI [78-99%]) for those without. PR was 25%, VGPR 33%, and CR/sCR 48%, with 65% achieving MRD-negativity. In terms of safety, hematologic AEs were common, with anemia reported in 86% of patients. Non-hematologic common AEs included CRS (83%, 5% grade ≥3) and hypocalcemia (63%, 10% grade ≥3). No significant publication bias was detected.Conclusion:GPRC5D is an active and safe target that shows promising results in the treatment of relapsed and/or refractory (R/R) MM and heavily pretreated patients.

100 项与 Babol University of Medical Sciences 相关的药物交易

登录后查看更多信息

100 项与 Babol University of Medical Sciences 相关的转化医学

登录后查看更多信息